The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.
First-in-Human T-Cell Therapy Warrants Further Investigation in HCCOctober 9th 2020
New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.
Bavituximab/Pembrolizumab Combo Is Active in Advanced Gastric/GEJ CancerOctober 6th 2020
The combination of bavituximab and pembrolizumab demonstrated synergistic antitumor activity and was well tolerated in patients with pretreated advanced gastric or gastroesophageal junction cancer.
Dr. Kristeleit on QoL With Dostarlimab in dMMR/MSI-H Endometrial CancerSeptember 30th 2020
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the importance of patient-reported outcomes in the phase 1 GARNET trial in advanced or recurrent mismatch repair deficient/microsatelite instability-high endometrial cancer.
Dr. McDermott on Rationale for Darolutamide Plus ADT/Radiation in High-Risk Prostate CancerSeptember 30th 2020
Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the rationale for the addition of darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk prostate cancer.
Dr. Eggermont on the Rationale for Evaluating Adjuvant Pembrolizumab in Advanced MelanomaSeptember 30th 2020
Alexander M. M. Eggermont, MD, PhD, discusses the rationale for the phase 3 EORTC 1325/KEYNOTE-054 trial, evaluating adjuvant pembrolizumab versus placebo, in advanced melanoma.